MilliporeSigma to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody
• MilliporeSigma plans to offer Phanes a full suite of products and services under its BioReliance® offering

Shanghai, China, July 24, 2019 — MilliporeSigma, a leading science and technology company, today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for a collaboration on the development and manufacture of biologics for the treatment of solid tumors.

“China is a key market for MilliporeSigma, and we are seeing increased demand for end-to-end process development solutions,” said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany, CEO MilliporeSigma. “We look forward to supporting our customers who are accelerating research and development and commercializing new therapies.”

The parties envision that under the alliance, MilliporeSigma would provide its BioReliance® End-to-End Solutions to Phanes, including cell line development, process development and GMP manufacturing up to commercialization. This includes the development and manufacturing of a Bispecific Antibody, an asset discovered with Phanes’ proprietary bispecific antibody platform which can simultaneously bind to two different targets or antigens on cancer cells, allowing the treatment of solid tumors.

With more than 30 years’ experience in process development and a global network of technical experts, MilliporeSigma's end-to-end team in Shanghai will be able to work seamlessly with their global organization to ensure a quick and smooth project start. MilliporeSigma’s BioReliance® End-to-End Solutions address key challenges for biopharmaceutical companies at all stages of molecule development and commercialization in any geography.

“As an innovative drug discovery company with a robust pipeline, we are looking for reliable partners with top notch caliber and measurement capabilities to quickly advance our premium molecules," said Dr. Ming Wang, CEO of Phanes. "We are very excited for the opportunity to partner with MilliporeSigma to advance our leading assets in the chemical manufacturing control stage. MilliporeSigma has a long and excellent track record in helping their global clients deliver high-quality materials for preclinical development and initiation of phase 1 studies. This collaboration will provide us access to MilliporeSigma’s global capabilities and high-quality systems, allowing us to continue to focus on what we do best at — building innovation in research. We look forward to a productive partnership.”

MilliporeSigma works side-by-side with biopharma customers on global clinical drug development and scaling processes at local production facilities. Additionally, the company has longstanding expertise in helping biopharma customers design and implement a full manufacturing process at their facilities or at MilliporeSigma’s own sites in Martillac, France; Burlington, Massachusetts, USA and Shanghai, China.